TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06185608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Description: A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
Study: NCT06231706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread and low fat spread
Description: Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
Study: NCT05172531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline 0.12ml/kg/hr
Description: saline 0.12ml/kg/hr
Study: NCT05239312

Intervention type: DRUG
Intervention: Antimicrobial
Description: Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
Study: NCT05705895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CENTRAL VENOUS CATHETER CARE PROTOCOL
Description: Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process.
Study: NCT05878977

Intervention type: DRUG
Group type: OTHER
Intervention: Immune checkpoint inhibitor
Description: Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
Study: NCT05596734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection
Study: NCT05500183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively enriched walking program
Description: The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
Study: NCT05596734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection
Study: NCT05500183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking program
Description: The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
Study: NCT06027879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific T- Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
Study: NCT06336343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
Study: NCT05596734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bIRV
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tIRV
Description: Intramuscular injection
Study: NCT05875844

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Wrist Splint
Description: Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
Study: NCT05271942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tilt and Tumble
Description: The Tilt and Tumble technique is used to remove the human lens.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Divide and Conquer
Description: The Divide and Conquer technique is used to remove the human lens.
Study: NCT06093399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System ON
Description: The DBS system will be turned on, and the individual's stutter will be assessed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System OFF
Description: The DBS system will be turned off, and the individual's stutter will be assessed.
Study: NCT05254756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bouquet speculum
Description: Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional plastic 2-blade disposable speculum
Description: Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
Study: NCT05340530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: Meropenem is a carbapenem antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: Meropenem is a carbapenem antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avibactam Sodium
Description: Avibactam is beta-lactamase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a placebo.
Study: NCT06130410

Intervention type: BIOLOGICAL
Intervention: COMIRNATY intramuscular injection
Description: Booster injection in the muscle, 1 dose
Study: NCT05712980

Intervention type: DEVICE
Intervention: Implanted pulse generator for SCS with different programming modalities
Description: Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization

Intervention type: DEVICE
Intervention: Implanted pulse generator for SCS with different programming modalities
Description: Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization
Study: NCT04729933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Shunt Placement
Description: After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
Study: NCT05317026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy only
Description: SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
Study: NCT06512779

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: sleep hygiene education

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Training (face-to-face)
Description: Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Training (telerehabilitation)
Description: Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
Study: NCT05135572

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fibromiyalgia and foot pain
Description: Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibromiyalgia and foot pain
Description: Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
Study: NCT05177419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: 100 micrograms LSD base

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: Low dose of LSD base
Study: NCT06400628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education
Description: The base line data will be taken and used as control, while the final result will be utilized as the case

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management education
Description: The base line data will be taken and used as control, while the final result will be utilized as the case
Study: NCT06078527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheung-Bearelly Aesthesiometer
Description: The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal Laryngoscopy
Description: A procedure to examine your larynx (voice box)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patient-reported health and behavioral outcomes measures will be administered
Study: NCT06715020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET scan.
Study: NCT06718309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical resection of lung cancer
Description: Radical resection of lung cancer with lymph node dissection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy
Study: NCT06717828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercise
Description: Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Exercise
Description: The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
Study: NCT04750070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: Children will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
Study: NCT04929067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Description: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Study: NCT05984212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided rectus sheath block with dexmedetomidine
Description: Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided rectus sheath block with normal saline
Description: Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)